United Therapeutics CORP Form 4 insider transactions

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned option exercises and subsequent sales of company common stock totaling 22,500 shares.

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $512.12 per share under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Louis W. Sullivan exercised stock options and subsequently sold all beneficially owned common stock through a trust on December 22, 2025.

United Therapeutics Director Tommy G Thompson exercised stock options and subsequently sold an equal number of common shares on December 18, 2025.

United Therapeutics CEO Martine Rothblatt completed the final transactions under a pre-arranged 10b5-1 trading plan, exercising options and selling common stock.

United Therapeutics CFO James Edgemond exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, CEO of United Therapeutics, executed planned stock option exercises and subsequent sales of common stock totaling 8,000 shares.

United Therapeutics' President and COO, Michael Benkowitz, executed a pre-planned sale of common stock following the exercise of stock options.

United Therapeutics Director Christopher Patusky exercised stock options and sold 1,000 shares of common stock in a pre-planned transaction.

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $482.98 per share under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 11,000 shares of common stock for approximately $5.3 million under a pre-arranged 10b5-1 plan.

United Therapeutics Corp. CEO Martine A. Rothblatt exercised and sold common stock options totaling 8,000 shares over two days in December 2025, pursuant to a pre-arranged trading plan.

United Therapeutics Corp. Director Nilda Mesa reported the sale of 187 common shares under a pre-arranged trading plan.

United Therapeutics CEO Martine Rothblatt reported the exercise of stock options and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics' CFO and Treasurer, James Edgemond, exercised stock options and subsequently sold a significant portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, executed pre-planned stock option exercises and subsequent sales of common stock totaling 22,500 shares.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed pre-planned stock option exercises and subsequent sales of common stock in early December 2025.

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock totaling 8,000 shares over two days.

United Therapeutics CFO James Edgemond executed a pre-planned sale of 21,000 common shares following the exercise of stock options.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold common stock shares in pre-arranged transactions.

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold common stock shares through a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock in late November 2025.

United Therapeutics CFO James Edgemond exercised 21,000 stock options and subsequently sold 21,000 common shares under a pre-arranged 10b5-1 plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and subsequently sold 22,500 shares of common stock for approximately $473.66 per share.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed pre-arranged sales of common stock and exercised options in late November 2025.

United Therapeutics CEO Martine A. Rothblatt exercised stock options and sold common stock on November 20 and 21, 2025, under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, exercised stock options and sold common stock shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics President and COO Michael Benkowitz exercised options and sold 22,500 shares under a Rule 10b5-1 plan on 11/17/2025.